These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9839623)

  • 41. [Several remarks on the technic used in the combined therapy with hyaluronidase & antibiotics in otology].
    TARLE Y
    Ann Otolaryngol; 1958 Dec; 75(12):967-9. PubMed ID: 13617803
    [No Abstract]   [Full Text] [Related]  

  • 42. [Use of hyaluronidase in chronic pneumonia].
    Pertsovskiĭ AI; Emel'kin VI; Chibireva EM
    Vrach Delo; 1976 Jan; (1):73-6. PubMed ID: 1246865
    [No Abstract]   [Full Text] [Related]  

  • 43. [EXPERIENCES IN LOCAL THERAPY OF MALIGNANT TUMORS BY INJECTION OF A CYTOSTATIC-HYALURONIDASE MIXTURE].
    LUECKE K
    Krebsarzt; 1964; 19():193-5. PubMed ID: 14188900
    [No Abstract]   [Full Text] [Related]  

  • 44. Ground Substance of the Mesenchyme and Hyaluronidase: A Symposium.
    Duran-Reynals F; Goldsmith ED
    Science; 1949 Jul; 110(2846):74-5. PubMed ID: 17774963
    [No Abstract]   [Full Text] [Related]  

  • 45. Ground substance of the mesenchyme and hyaluronidase.
    GOLDSMITH ED
    Nature; 1949 Jan; 163(4135):184. PubMed ID: 18107589
    [No Abstract]   [Full Text] [Related]  

  • 46. The ground substance of the mesenchyme hyaluronidase; introduction.
    DURAN-REYNALS F
    Ann N Y Acad Sci; 1950 May; 52(7):946-57. PubMed ID: 15426108
    [No Abstract]   [Full Text] [Related]  

  • 47. The fundamental role of hyaluronidase in tissue.
    Bok SW
    Med Hypotheses; 1979 Nov; 5(11):1183-200. PubMed ID: 537539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Cytostatic impact therapy with trisethyleniminobenzochinone].
    Siering H; Reinhardt M
    Z Gesamte Inn Med; 1966 Oct; 21(20):Suppl:264-6. PubMed ID: 5996793
    [No Abstract]   [Full Text] [Related]  

  • 49. The present status of synergistic and additive chemotherapy.
    KOLMER JA
    Tex State J Med; 1948 Jun; 44(2):81-5. PubMed ID: 18868576
    [No Abstract]   [Full Text] [Related]  

  • 50. The present status of synergistic and additive chemotherapy.
    KOLMER JA
    Hahnemann Mon; 1948 Jun; 83(6):226-36. PubMed ID: 18861058
    [No Abstract]   [Full Text] [Related]  

  • 51. Targets in the Tumour Matrisome to Promote Cancer Therapy Response.
    Jalil SMA; Henry JC; Cameron AJM
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791926
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hyaluronic acid metabolism and chemotherapy resistance: recent advances and therapeutic potential.
    Liu Z; Hou P; Fang J; Shao C; Shi Y; Melino G; Peschiaroli A
    Mol Oncol; 2024 Sep; 18(9):2087-2106. PubMed ID: 37953485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted Depletion of Hyaluronic Acid Mitigates Murine Breast Cancer Growth.
    Zamloot V; Ebelt ND; Soo C; Jinka S; Manuel ER
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230537
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deep learning identification of stiffness markers in breast cancer.
    Sneider A; Kiemen A; Kim JH; Wu PH; Habibi M; White M; Phillip JM; Gu L; Wirtz D
    Biomaterials; 2022 Jun; 285():121540. PubMed ID: 35537336
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The scrambled story between hyaluronan and glioblastoma.
    Pibuel MA; Poodts D; Díaz M; Hajos SE; Lompardía SL
    J Biol Chem; 2021; 296():100549. PubMed ID: 33744285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC.
    Sharma M; Turaga RC; Yuan Y; Satyanarayana G; Mishra F; Bian Z; Liu W; Sun L; Yang J; Liu ZR
    J Exp Med; 2021 Apr; 218(4):. PubMed ID: 33561195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent Research on Methods to Improve Tumor Hypoxia Environment.
    Zhu XH; Du JX; Zhu D; Ren SZ; Chen K; Zhu HL
    Oxid Med Cell Longev; 2020; 2020():5721258. PubMed ID: 33343807
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers.
    Printz MA; Dychter SS; DeNoia EP; Harrigan R; Sugarman BJ; Zepeda M; Souratha J; Kang DW; Maneval DC
    Curr Ther Res Clin Exp; 2020; 93():100604. PubMed ID: 32963641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Towards extracellular matrix normalization for improved treatment of solid tumors.
    Abyaneh HS; Regenold M; McKee TD; Allen C; Gauthier MA
    Theranostics; 2020; 10(4):1960-1980. PubMed ID: 32042347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hyaluronidase-Expressing
    Ebelt ND; Zuniga E; Passi KB; Sobocinski LJ; Manuel ER
    Mol Cancer Ther; 2020 Feb; 19(2):706-716. PubMed ID: 31694889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.